Hospira Epirubicin Hydrochloride Injection 150 mg/75 mL Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira epirubicin hydrochloride injection 150 mg/75 ml vial

hospira australia pty ltd - epirubicin hydrochloride -

Hospira Vinorelbine Tartrate for injection vial 10 mg/1 mL Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine tartrate for injection vial 10 mg/1 ml

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. it is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Hospira Vinorelbine Tartrate 50 mg/5 mL Injection vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine tartrate 50 mg/5 ml injection vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated in combination with cisplatin.

Hospira VINORELBINE 10 mg/mL sterile concentrate 50 mg/5 mL vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine 10 mg/ml sterile concentrate 50 mg/5 ml vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection - excipient ingredients: water for injections - non-small cell lung cancer (stage 3 or 4). as single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline - and taxane containing chemotherapy has failed or is not appropriate.

Hospira Paclitaxel 6 mg/mL Concentrated Solution for Infusion, 150 mg/25 mL Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel 6 mg/ml concentrated solution for infusion, 150 mg/25 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - paclitaxel is indicated, in combination with other drugs, for treating certain diseases of the ovary, breast and lung cancer, of kaposi's sarcoma linked to aids and where cellular growth is altered.

Hospira Paclitaxel 6 mg/mL Concentrated Solution for Infusion, 30 mg/5 mL Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel 6 mg/ml concentrated solution for infusion, 30 mg/5 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: ethanol absolute; citric acid; peg-35 castor oil - paclitaxel is indicated, in combination with other drugs, for the treatment of certain diseases of ovary, breast and lung, of sarcoma of kaposi tied to aids and where cellular growth is altered.

Hospira Vinorelbine 10 mg/1 mL Sterile Concentrate Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine 10 mg/1 ml sterile concentrate vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated in the treatment of: - non-small cell lung cancer (stage 3 or 4) - as a single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline- and taxane containing chemotherapy has failed or is not appropriate

Hospira Vinorelbine Tartrate10 mg/1 mL Injection Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine tartrate10 mg/1 ml injection vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated with in combination with cisplatin.

Hospira Vinorelbine Tartrate for Injection 50 mg/5 mL vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira vinorelbine tartrate for injection 50 mg/5 ml vial

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Hospira Paclitaxel Concentrate for Solution for Infusion 30 mg/5 mL Vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

hospira paclitaxel concentrate for solution for infusion 30 mg/5 ml vial

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: ethanol absolute; peg-35 castor oil; citric acid - ovarian cancer: ??in first-line chemotherapy paclitaxel is indicated for the treatment of patients with advanced disease or a residual disease (>1 cm) after initial laparotomy, in combination with cisplatin. ??in second-line chemotherapy paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy. breast cancer: ??in the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (ac) therapy. adjuvant treatment with paclitaxel should be regarded as an alternative to extended ac therapy. ??paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (her-2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. ??as a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate, or relapse within 6 months of adjuvant chemotherapy. advanced non-small cell lung cancer (nsclc): ??paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy. aids-related kaposi?s sarcoma (ks): ??paclitaxel is indicated for the treatment of patients with advanced aids-related ks who have failed prior liposomal anthracycline therapy.